Security
IceCure Medical Ltd. Ordinary Shares · ICCM
ICCMNASDAQCommon stockCurrentCIK 1584371Updated Oct 14, 2026
ICCM price & chart
Loading TradingView…
NASDAQ:ICCM on TradingView ↗About the company
IceCure Medical (Nasdaq: ICCM) develops and markets advanced liquid-nitrogen-based cryoablation therapy systems for the destruction of tumors (benign and cancerous) by freezing, as a safe and effective minimally invasive option to surgical tumor removal, with the primary focus areas being breast, kidney, bone and lung cancer. The Company’s flagship ProSense® system is marketed and sold worldwide for the indications cleared and approved to date including in the U.S., Europe, and Asia.
In the news
IceCure Announces Pricing of $4.0 Million Registered Direct Offering and Concurrent Private Placement ↗
Recent filings
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 13,888,000Source | 12,576,000Source | 16,410,000Source | 30,188,000Source |
| Property, Plant and Equipment, NetUSD | 993,000Source | 1,252,000Source | 1,513,000Source | 1,356,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 8,897,000Source | 7,564,000Source | 10,533,000Source | 23,659,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | — | 221,000Source | 103,000Source | 78,000Source |
| Inventory, NetUSD | 2,625,000Source | 1,988,000Source | 2,275,000Source | 2,857,000Source |
| Assets, CurrentUSD | 12,605,000Source | 10,754,000Source | 14,184,000Source | 28,130,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 752,000Source | 981,000Source | 744,000Source | — |
| Operating Lease, Right-of-Use AssetUSD | 239,000Source | 524,000Source | 679,000Source | — |
| LIABILITIES AND EQUITY | ||||
| Stockholders’ equity: | ||||
| Additional Paid in CapitalUSD | — | 112,280,000Source | 102,224,000Source | 100,831,000Source |
| Retained Earnings (Accumulated Deficit)USD | -120,436,000Source | -105,379,000Source | -90,061,000Source | -75,409,000Source |
| Stockholders' Equity Attributable to ParentUSD | 9,051,000Source | 6,901,000Source | 12,163,000Source | 25,422,000Source |
| Additional Paid in Capital, Common StockUSD | 129,487,000Source | — | — | — |
| Liabilities and EquityUSD | 13,888,000Source | 12,576,000Source | 16,410,000Source | 30,188,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 4,824,000Source | 5,514,000Source | 3,871,000Source | 4,336,000Source |
| Operating Lease, Liability, CurrentUSD | 204,000Source | 298,000Source | 223,000Source | 167,000Source |
| Accounts Payable, CurrentUSD | — | — | 502,000Source | 714,000Source |
| Operating Lease, Liability, NoncurrentUSD | — | 161,000Source | 376,000Source | 430,000Source |
| Additional Financial Items | ||||
| Accounts Receivable, after Allowance for Credit LossUSD | — | 3,000Source | — | — |
| Deferred Revenue, CurrentUSD | 255,000Source | — | 187,000Source | 646,000Source |
| Long-term Debt, Excluding Current MaturitiesUSD | 13,000Source | — | — | — |
| Short-term InvestmentsUSD | — | — | 529,000Source | — |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | -16,978,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | 1,373,000Source | 869,000Source | 1,310,000Source | 1,865,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | 110,000Source | 118,000Source | 25,000Source | -378,000Source |
| Increase (Decrease) in InventoriesUSD | 637,000Source | -287,000Source | -582,000Source | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -14,574,000Source | -12,563,000Source | -12,521,000Source | -14,292,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -36,000Source | 446,000Source | -713,000Source | -891,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 36,000Source | 71,000Source | 480,000Source | 891,000Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 15,834,000Source | 9,187,000Source | 83,000Source | 13,577,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | -1,606,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 8,897,000Source | 7,564,000Source | 10,533,000Source | 23,659,000Source |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 109,000Source | — | — | — |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | — | 1,865,000Source |
| DepreciationUSD | 295,000Source | 332,000Source | 323,000Source | 248,000Source |
| General and Administrative ExpenseUSD | 4,529,000Source | 3,755,000Source | 4,166,000Source | 5,857,000Source |
| Inventory Write-downUSD | 126,000Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | -15,057,000Source | -15,318,000Source | -14,652,000Source | -16,978,000Source |
| Nonoperating Income (Expense)USD | 37,000Source | 378,000Source | 924,000Source | -239,000Source |
| Operating Lease, ExpenseUSD | — | — | 599,000Source | — |
| Proceeds from Issuance of Common StockUSD | — | 9,187,000Source | — | 13,569,000Source |
| Proceeds from Stock Options ExercisedUSD | — | — | 83,000Source | — |
| Revenue from Contract with Customer, Including Assessed TaxUSD | — | — | 3,229,000Source | — |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 3,379,000Source | 3,291,000Source | 3,229,000Source | 3,085,000Source |
| Cost of Goods and Services Sold | — | — | — | — |
| Selling, General and Administrative ExpenseUSD | — | — | — | 735,000Source |
| Operating Income (Loss)USD | -15,094,000Source | -15,696,000Source | -15,576,000Source | -16,739,000Source |
| Net Income (Loss) Attributable to ParentUSD | -15,057,000Source | -15,318,000Source | -14,652,000Source | -16,978,000Source |
| Earnings Per Share, BasicUSD per share | 0.24Source | 0.3Source | 0.32Source | 0.46Source |
| Earnings Per Share, DilutedUSD per share | 0.24Source | 0.3Source | 0.32Source | 0.46Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 63,579,251Source | 50,876,790Source | 45,638,030Source | 37,016,631Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 63,579,251Source | 50,876,790Source | 45,638,030Source | 37,016,631Source |
| Additional Financial Items | ||||
| General and Administrative ExpenseUSD | 4,529,000Source | 3,755,000Source | 4,166,000Source | 5,857,000Source |
| Gross ProfitUSD | 1,226,000Source | 1,451,000Source | 1,300,000Source | 1,445,000Source |
| Income (Loss) Attributable to Parent, before TaxUSD | -15,057,000Source | — | — | — |
| Labor and Related ExpenseUSD | — | — | 1,886,000Source | — |
| Marketing and Advertising ExpenseUSD | — | — | 92,000Source | 74,000Source |
| Nonoperating Income (Expense)USD | 37,000Source | 378,000Source | 924,000Source | -239,000Source |
| Operating Lease, ExpenseUSD | — | — | 599,000Source | — |
| Other Cost of Operating RevenueUSD | 150,000Source | 94,000Source | 174,000Source | — |
| Other ExpensesUSD | — | — | — | 512,000Source |
| Other General and Administrative ExpenseUSD | — | — | 284,000Source | 226,000Source |
| Other General ExpenseUSD | — | — | — | 917,000Source |
| Research and Development ExpenseUSD | 7,433,000Source | 7,096,000Source | 8,273,000Source | 9,123,000Source |
| Revenue from Contract with Customer, Including Assessed TaxUSD | — | — | 3,229,000Source | — |
| Selling and Marketing ExpenseUSD | 4,358,000Source | 6,296,000Source | 4,437,000Source | 3,204,000Source |
| Selling ExpenseUSD | — | — | — | 3,204,000Source |
Offerings
Registration 333-288062
Registration 333-294827
Registration 333-297030
Registration 333-290046
Filing attachments
ea030843901ex99-1.htm · 6-K · 2026-10-13
Exhibit 99.1 IceCure Highlights Clinical Data and Strong Physician Engagement for ProSense® Breast Cancer Cryoablation at EUSOBI 2026 Scientific presentations, research posters and clinical workshops featured ProSense® breast cancer cryoablation and highlighted strong physician engagement across Europe CAESAREA, Israel, October 13, 2026 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) (“IceCure,” “IceCure Medical” or the “Company”), developer of minimally-invasive cryoablation technology t…
Read attachment ↗ea030766101ex99-1.htm · 6-K · 2026-10-05
Exhibit 99.1 Dear IceCure Medical Ltd. Shareholder: We cordially invite you to attend the Annual and Special General Meeting of Shareholders (the “Meeting”) of IceCure Medical Ltd. (the “Company”), to be held on Monday, November 2, 2026, at 5:00 p.m. Israel time, or at any adjournment or postponement thereof, by means of remote communication at the following link: Join the meeting now https://teams.microsoft.com/meet/349648358702503?p=dbGcvXV8mxJQEpPtgj At the Meeting, shareholders will be …
Read attachment ↗ea030766101ex99-2.htm · 6-K · 2026-10-05
Exhibit 99.2 ICECURE MEDICAL LTD. CAESAREA, ISRAEL PROXY STATEMENT ANNUAL AND SPECIAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON NOVEMBER 2, 2026 This proxy statement (the “Proxy Statement”) is being solicited by the board of directors (the “Board of Directors”) of IceCure Medical Ltd. (the “Company”) for use at the Company’s annual and special general meeting of shareholders (the “Meeting”) to be held at on Monday, November 2, 2026 at 5:00 p.m. Israel time, or at any adjournment or postp…
Read attachment ↗ea030678801ex99-1.htm · 6-K · 2026-09-28
Exhibit 99.1 Dear IceCure Medical Ltd. Shareholder: We cordially invite you to attend the Annual and Special General Meeting of Shareholders (the “Meeting”) of IceCure Medical Ltd. (the “Company”), to be held on Monday, November 2, 2026, at 5:00 p.m. Israel time, or at any adjournment or postponement thereof, by means of remote communication at the following link: Join the meeting now https://teams.microsoft.com/meet/349648358702503?p=dbGcvXV8mxJQEpPtgj At the Meeting, shareholders will be …
Read attachment ↗ea030678801ex99-2.htm · 6-K · 2026-09-28
Exhibit 99.2 ICECURE MEDICAL LTD. CAESAREA, ISRAEL PROXY STATEMENT ANNUAL AND SPECIAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON NOVEMBER 2, 2026 This proxy statement (the “Proxy Statement”) is being solicited by the board of directors (the “Board of Directors”) of IceCure Medical Ltd. (the “Company”) for use at the Company’s annual and special general meeting of shareholders (the “Meeting”) to be held at on Monday, November 2, 2026 at 5:00 p.m. Israel time, or at any adjournment or postp…
Read attachment ↗ea030509601ex99-1.htm · 6-K · 2026-09-10
Exhibit 99.1 IceCure Medical Receives Regulatory Approval to Market ProSense ® in China CAESAREA, Israel, September 10, 2026 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) (“IceCure,” “IceCure Medical” or the “Company”), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced that it has received approval, as a Class III medical device, from China’s National Medical Products Administration (“NMPA”) fo…
Read attachment ↗